Русский
Results of treatment with a 60-week Russian ART regimen in patients with HIV infection
DOI: https://dx.doi.org/10.18565/epidem.2021.11.3.90-5
Kravchenko A.V., Pokrovskaya A.V., Kuimova U.A., Kanestri V.G., Deulina M.O., Goliusova M.D., Kulabukhova E.I., Kozyrina N.V., Yurin O.G.
1) Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; 2) Peoples’ Friendship University of Russia, Moscow, Russia
Subjects and methods. The investigation enrolled 98 HIV-infected patients who had not previously received ART. As of April 1, 2021, 90, 80, and 72 patients completed 24-, 48- and 60- week treatment, respectively. The investigation is being continued. 73.5% of the patients were men. The patients’ age ranged from 22 to 70 years (the median age was 35 years). Before starting therapy, the median CD4+ lymphocyte count was 449 cells/µl; the immunoregulatory index (CD4/CD8 lymphocyte ratio) was equal to 0.458. The median HIV RNA was 15,286 copies/ml.
Results. At 4 and 12 weeks after starting ART, the patients with a HIV RNA level of < 50 copies/ml were 45.9% and 80%, respectively. At 24, 48, and 60 weeks, the patients achieved undetectable HIV RNA levels in 95.4%, 100%, and 95.3%, respectively. After 24, 48, and 60 weeks of the investigation, the increase in the median CD4+ lymphocyte count was 62, 173, and 190 cells/µl, respectively. The median immunoregulatory index was recorded to increase up to 0.828 at 60 weeks of ART. The tolerability of the ART regimen was good: 92.5–95% of the patients noticed no therapy-related adverse events (AEs). At the beginning of therapy, most of the AEs were generally found to be mild and to require no correction of the treatment regimen or the use of additional therapy.
Conclusion. The Russian combination of drugs, including P-AZT + 3TS + ESV, was highly effective and safe during 60-weeks treatment in HIV-infected of patients who had not previously received ART. The use of ESV in combination not only with TDF and FTC, but also with P-AZT and 3TS can be recommended in the first-line ART regimens.
Literature
1. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). December 18, 2019. https://www.AIDSinfo.nih.gov 2. Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 10.0; November 2019). European AIDS Clinical Society. http://www.eacsociety.org 3. Обновление рекомендаций по антиретровирусной терапии первой и второй линии. Женева, Швейцария: ВОЗ, 2019. Лицензия: CC BY-NC-SA 3.0 IGO. http://apps.who.int/iris [Updating the recommendations for first-and second-line antiretroviral therapy]. Geneva, Switzerland: WHO, 2019. (WHO/CDS/HIV/19.15). (In Russ.). http://apps.who.int/iris 4. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Буравцова Е.В., Деулина М.О. и др. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ. Эпидемиол. инфекц. болезни. Актуал. вопр. 2020; 10 (4, приложение), 92 с. Pokrovsky V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Buravtsova E.E., Deulina M.O. et al. [Recommendations for the treatment of HIV infection and related diseases, chemoprophylaxis of HIV infection]. Epidemiology and infectious diseases. Current items 2020; 10 (4, Suppl.). 92 р. (In Russ.). 5. Кравченко А.В., Орлова-Морозова Е.А., Шимонова Т.Е. Козырев О.А., Нагимова Ф.И., Захарова Н.Г. и др. Эффективность и безопасность нового российского ненуклеозидного ингибитора обратной транскриптазы элсульфавирина в сочетании с тенофовиром/эмтрицитабином – многоцентровое сравнительное исследование с эфавирензом у пациентов с ВИЧ-инфекцией, ранее не получавших лечение. Инфекционные болезни 2017; 15(3): 5–13. Kravchenko A.V., Orlova-Morozova E.A., Shimonova T.E., Kozyrev O.A., Nagimova F.I., Zakharova N.G. et al. [Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with tenofovir/emtricitabine – multicenter comparative trial vs efavirenz in naїve HIV patients]. Infectious Diseases 2017; 15(3): 5–13. (In Russ.). 6. Кравченко А.В., Орлова-Морозова Е.А., Шимонова Т.Е., Козырев О.А., Нагимова Ф.И., Захарова Н.Г. и др. Эффективность и безопасность нового российского ненуклеозидного ингибитора обратной транскриптазы элсульфавирина в первой линии лечения ВИЧ-инфекции в комбинации с двумя нуклеозидными/нуклеотидными ингибиторами обратной транскриптазы – исследование 96 недель. Журнал Инфектологии 2018; 10(2), 76–82. DOI: 10.22625/2072-6732-2018-10-2-76-82 Kravchenko A.V., Orlova-Morozova E.A., Shimonova T.E., Kozyrev O.A., Nagimova F.I., Zakharova N.G. et al. [Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study]. Journal Infectology 2018; 10(2): 76–82. (In Russ.). DOI: 10.22625/2072-6732-2018-10-2-76-82 7. Кравченко А.В., Куимова У.А., Ефремова О.С., Иванова Э.С., Попова А.А. Сравнение эффективности и безопасности схем антиретровирусной терапии первой линии, включавших фосфазид или тенофовир. Журнал Инфектологии 2018; 10(4), 37–41. DOI: 10.22625/2072-6732-2018-10-4-37-41 Kravchenko А.V., Kuimova U.A., Efremova O.S., Ivanova E.S., Popova A.A. [Comparison of efficacy and safety of antiretroviral first-line therapy with phosphazide or TDF]. Journal Infectology 2018; 10(4): 37–41. (In Russ.). DOI: 10.22625/2072-6732-2018-10-4-37-41
About the Autors
Professor Alexey V. Kravchenko, МD, Leading Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being; alexey-kravtchenko@yandex.ru; http://orcid.org/0000-0001-7857-3763
Anastasia V. Pokrovskaya, Cand. Med. Sci., Senior Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; Associate Professor, Department of Infectious Diseases with Courses of Epidemiology and Phthisiology, Medical Institute, Peoples’ Friendship University; pokrovskaya_av@mail.ru; http://orcid.org/0000-0002-2677-0404
Ulyana A. Kuimova, Cand. Med. Sci., Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; ulyanakuimova@gmail.com; https://orcid.org/0000-0002-1101-151X
Veronika G. Kanestri, MD, Senior Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; kanestri@yandex.ru; http://orcid.org/0000-0002-2234-7094
Marina O. Deulina, Researcher, Central Research Institute of Epidemiology Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; de-marik@yandex.ru
Marina D. Goliusova, Infectiologist, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; mad2501@yandex.ru; https://orcid.org/0000-0002-5325-6857
Ekaterina I. Kulabuhova, Infectiologist, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance of Consumer Rights Protection and Human Well-Being; Head, Laboratory of the Department of Infectious Diseases with Courses of Epidemiology and Phthisiology, Medical Institute, Peoples’ Friendship University; ekulabukhova@mail.ru; http://orcid.org/0000-0003-3645-7275
Nadezhda V. Kozyrina, Cand. Med. Sci., Senior Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance oа Consumer Rights Protection and Human Well-Being; nad-kozyrina@yandex.ru; htpp://orcid.org/0000-0001-5134-0054
Oleg G. Yurin, МD, Leading Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance oа Consumer Rights Protection and Human Well-Being; oleg_gerald@mail.ru; htpp://orcid.org/0000-0003-1930-7486
Similar Articles
